If ozekibart makes it to market, it could face competition from Servier Pharmaceuticals’ IDH inhibitor, Tibsovo (ivosidenib), which is currently in Phase III for conventional chondrosarcoma. Bristol ...

Ivosidenib combined with azacitidine extended median overall survival to 29.3 months compared with 7.9 months for placebo plus azacitidine in newly diagnosed isocitrate dehydrogenase 1 (IDH1)-mutated ...

Long-term efficacy and safety results published in Blood Advances continue to demonstrate the sustained survival benefit of adding TIBSOVO to azacitidine in IDH1-mutated AML Data support the use of ...

Servier India, a subsidiary of the leading French pharmaceutical Servier Group, recently announced the launch of Ivosidenib (Tibsovo), an oral targeted therapy approved in the management of cancer ...

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits Yearly Premium ₹999 ₹349/Year SUBSCRIBE NOW Yearly ...

Discover comprehensive details about Ivosidenib, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Alembic Pharmaceuticals Limited on Thursday announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for ...

The tentative approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Ivosidenib tablets of strength 250 mg, the company said in a regulatory ...

Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: (a) newly diagnosed acute myeloid ...

Alembic Pharmaceuticals on Thursday received tentative approval from the US health regulator for its generic Ivosidenib tablets used in the treatment of certain types of cancer of bone marrow and bile ...

The evaluation committee considered evidence submitted by Servier Laboratories, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee ...